Cargando…

Hydroxychloroquine synergizes with the PI3K inhibitor BKM120 to exhibit antitumor efficacy independent of autophagy

BACKGROUND: The critical role of phosphoinositide 3-kinase (PI3K) activation in tumor cell biology has prompted massive efforts to develop PI3K inhibitors (PI3Kis) for cancer therapy. However, recent results from clinical trials have shown only a modest therapeutic efficacy of single-agent PI3Kis in...

Descripción completa

Detalles Bibliográficos
Autores principales:	Peng, Xin, Zhang, Shaolu, Jiao, Wenhui, Zhong, Zhenxing, Yang, Yuqi, Claret, Francois X., Elkabets, Moshe, Wang, Feng, Wang, Ran, Zhong, Yuxu, Chen, Zhe-Sheng, Kong, Dexin
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	BioMed Central 2021
Materias:	Research
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8628289/ https://www.ncbi.nlm.nih.gov/pubmed/34844627 http://dx.doi.org/10.1186/s13046-021-02176-2

Ejemplares similares

Correction to: Hydroxychloroquine synergizes with the PI3K inhibitor BKM120 to exhibit antitumor efficacy independent of autophagy
por: Peng, Xin, et al.
Publicado: (2021)

BKM120 sensitizes glioblastoma to the PARP inhibitor rucaparib by suppressing homologous recombination repair
por: Zhang, Shaolu, et al.
Publicado: (2021)

Stellettin B Sensitizes Glioblastoma to DNA‐Damaging Treatments by Suppressing PI3K‐Mediated Homologous Recombination Repair
por: Peng, Xin, et al.
Publicado: (2022)

Oncolytic Herpes Simplex Virus and PI3K Inhibitor BKM120 Synergize to Promote Killing of Prostate Cancer Stem-like Cells
por: Wang, Lei, et al.
Publicado: (2019)

Activity of BKM120 and BEZ235 against Lymphoma Cells
por: Civallero, Monica, et al.
Publicado: (2015)

Inhibitory effect of NVP-BKM120 on cholangiocarcinoma cell growth
por: Padthaisong, Sureerat, et al.
Publicado: (2018)

BKM120 induces apoptosis and inhibits tumor growth in medulloblastoma
por: Zhao, Ping, et al.
Publicado: (2017)

Antitumor effects and mechanisms of olaparib in combination with carboplatin and BKM120 on human triple-negative breast cancer cells
por: Zhao, Hui, et al.
Publicado: (2018)

Stellettin B renders glioblastoma vulnerable to poly (ADP-ribose) polymerase inhibitors via suppressing homology-directed repair
por: Peng, Xin, et al.
Publicado: (2023)

PI3K Inhibition by BKM120 Results in Antiproliferative Effects on Corticotroph Tumor Cells
por: Oliveira, Helen A, et al.
Publicado: (2021)

NVP-BKM120, a novel PI3K inhibitor, shows synergism with a STAT3 inhibitor in human gastric cancer cells harboring KRAS mutations
por: PARK, EUNJU, et al.
Publicado: (2011)

Targeting Phosphatidylinositide3-Kinase/Akt pathway by BKM120 for radiosensitization in hepatocellular carcinoma
por: Liu, Wei-Lin, et al.
Publicado: (2014)

DT-13 Inhibits Proliferation and Metastasis of Human Prostate Cancer Cells Through Blocking PI3K/Akt Pathway
por: Wang, Zhengming, et al.
Publicado: (2018)

PI3k inhibitors (BKM120 and BYL719) as radiosensitizers for head and neck squamous cell carcinoma during radiotherapy
por: Chuang, Fu-Cheng, et al.
Publicado: (2021)

Corrigendum: DT-13 Inhibits Proliferation and Metastasis of Human Prostate Cancer Cells Through Blocking PI3K/Akt Pathway
por: Wang, Zhengming, et al.
Publicado: (2020)

BKM-120 (Buparlisib): A Phosphatidyl-Inositol-3 Kinase Inhibitor with Anti-Invasive Properties in Glioblastoma
por: Speranza, Maria-Carmela, et al.
Publicado: (2016)

Phase II study of BKM120 in patients with advanced esophageal squamous cell carcinoma (EPOC1303)
por: Kojima, Takashi, et al.
Publicado: (2022)

Effective use of PI3K inhibitor BKM120 and PARP inhibitor Olaparib to treat PIK3CA mutant ovarian cancer
por: Wang, Dong, et al.
Publicado: (2016)

Digoxin Enhances the Anticancer Effect on Non-Small Cell Lung Cancer While Reducing the Cardiotoxicity of Adriamycin
por: Wang, Yingying, et al.
Publicado: (2020)

Evaluation of In Vitro Activity of the Class I PI3K Inhibitor Buparlisib (BKM120) in Pediatric Bone and Soft Tissue Sarcomas
por: Anderson, Jennifer L., et al.
Publicado: (2015)

Apoptin Overexpression Efficiently Amplified Cytotoxic Effects of PI3K Inhibition Using BKM120 in Lymphoblastic Leukemia Cell Lines
por: Anjam-Najmedini, Ali, et al.
Publicado: (2022)

NVP-BKM120 inhibits colon cancer growth via FoxO3a-dependent PUMA induction
por: Yang, Shida, et al.
Publicado: (2017)

BKM120 sensitizes C6 glioma cells to temozolomide via suppression of the PI3K/Akt/NF-κB/MGMT signaling pathway
por: Li, Mao, et al.
Publicado: (2017)

Blockade efficacy of MEK/ERK-dependent autophagy enhances PI3K/Akt inhibitor NVP-BKM120's therapeutic effectiveness in lung cancer cells
por: Ren, Hui, et al.
Publicado: (2016)

Effects of PI3K inhibitor NVP-BKM120 on overcoming drug resistance and eliminating cancer stem cells in human breast cancer cells
por: Hu, Y, et al.
Publicado: (2015)

BKM120 sensitizes BRCA-proficient triple negative breast cancer cells to olaparib through regulating FOXM1 and Exo1 expression
por: Li, Yu, et al.
Publicado: (2021)

Disulfiram and BKM120 in Combination with Chemotherapy Impede Tumor Progression and Delay Tumor Recurrence in Tumor Initiating Cell-Rich TNBC
por: Wu, Ling, et al.
Publicado: (2019)

Treatment with the PI3K inhibitor buparlisib (NVP-BKM120) suppresses the growth of established patient-derived GBM xenografts and prolongs survival in nude rats
por: Netland, I. A., et al.
Publicado: (2016)

Phase 2 study of buparlisib (BKM120), a pan-class I PI3K inhibitor, in patients with metastatic triple-negative breast cancer
por: Garrido-Castro, Ana C., et al.
Publicado: (2020)

BKM-react, an integrated biochemical reaction database
por: Lang, Maren, et al.
Publicado: (2011)

Phase I dose-escalation study of buparlisib (BKM120), an oral pan-class I PI3K inhibitor, in Japanese patients with advanced solid tumors
por: Ando, Yuichi, et al.
Publicado: (2014)

The pan-class I phosphatidyl-inositol-3 kinase inhibitor NVP-BKM120 demonstrates anti-leukemic activity in acute myeloid leukemia
por: Allegretti, Matteo, et al.
Publicado: (2015)

Atorvastatin Exerts Antileukemia Activity via Inhibiting Mevalonate-YAP Axis in K562 and HL60 Cells
por: Zhang, Lei, et al.
Publicado: (2019)

Erratum: The pan-class I phosphatidyl-inositol-3 kinase inhibitor NVP-BKM120 demonstrates anti-leukemic activity in acute myeloid leukemia
por: Allegretti, Matteo, et al.
Publicado: (2016)

A Phase Ib/II, open-label, multicenter study of INC280 (capmatinib) alone and in combination with buparlisib (BKM120) in adult patients with recurrent glioblastoma
por: van den Bent, Martin, et al.
Publicado: (2019)

Mouse–human co-clinical trials demonstrate superior anti-tumour effects of buparlisib (BKM120) and cetuximab combination in squamous cell carcinoma of head and neck
por: Kim, Hye Ryun, et al.
Publicado: (2020)

Phase II study of the PI3K inhibitor BKM120 in patients with advanced or recurrent endometrial carcinoma: a stratified type I–type II study from the GINECO group
por: Heudel, P-E, et al.
Publicado: (2017)

Discovery of Novel PI3Kδ Inhibitors Based on the p110δ Crystal Structure
por: Jia, Wenqing, et al.
Publicado: (2022)

Stellettin B induces apoptosis in human chronic myeloid leukemia cells via targeting PI3K and Stat5
por: Chen, Yali, et al.
Publicado: (2017)

NVP-BKM120 potentiates apoptosis in tumor necrosis factor-related apoptosis-inducing ligand-resistant glioma cell lines via upregulation of Noxa and death receptor 5
por: FOSTER, KIMBERLY A., et al.
Publicado: (2015)

Cannot write session to /tmp/vufind_sessions/sess_paecqspaivfle47rt3u001fj02